Agilent Technologies Inc. and National University of Singapore Launch Center of Excellence in Cell Metabolism to Improve Population Health

Published: 2024-10-03 21:00:00 ET A

Agilent Technologies Inc. announced a new strategic partnership with National University of Singapore (NUS), acting through the Yong Loo Lin School of Medicine (NUS Medicine), to establish the NUS-Agilent Center of Excellence (CoE) in Cell Metabolism, a scientific collaboration to advance cardiovascular and metabolic disease translational research over the next four years. Metabolism is an increasingly important field of study to identify cardio-liver-metabolic biomarkers to prevent cardiovascular diseases, including heart attack and stroke. In Singapore, on average, 34 people have heart attacks daily and 25% are clinically silent.

Research advancements in this area can help discover meaningful clinical interventions for asymptomatic individuals to improve population health. As part of the collaboration, Agilent is providing its game-changing xCELLigence, Seahorse XF and BioTek technologies to support targeted and untargeted metabolic profiling for large-scale population-based cohorts across translational research. The CoE is part of Project RESET, a five-year government-funded research initiative focused on developing new early detection methods for cardiovascular diseases and elevating Singapore's global prominence in precision medicine.

The integrated use of Agilent's metabolic and cellular phenotyping platforms will provide a world-class multimodal workflow solution to study cells at unrivalled speed and scale. The NUS-Agilent CoE also supports the Cardiovascular Metabolic Disease Translational Research Programme (CVMD-TRP) and Preclinical Platform for Development of Therapeutics for Heart Failure (PREVENT-HF) at NUS Medicine to accelerate the discovery of novel insights into the complex mechanisms of heart disease.